To avoid this potential bias, we have performed a retrospective study on the prognostic impact of HER-2/neu in a historical cohort of node-negative T1/T2 breast cancer patients who were at that time not being treated in an adjuvant setting. The gene discussed is ERBB2; the disease is breast carcinoma.